MLV & Co

In a report published Tuesday, MLV & Co analyst Jonathan Petersen initiated coverage on Brandywine Realty Trust (NYSE: BDN) with a Buy rating and $17.00 price target. In the report, MLV & Co noted, “We like BDN's efforts over the past few years to focus its portfolio on the submarkets...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on XOMA Corp. (NASDAQ: XOMA) from Buy to Hold, and lowered the price target from $8.00 to $7.00. In the report, MLV & Co noted, “Following 1) negative P2 data for gevokizumab (gevo) last week in...

In a report published Thursday, MLV & Co analyst Richard Eckert downgraded the rating on New York Mortgage Trust (NASDAQ: NYMT) from Buy to Hold, but raised the price target from $7.50 to $7.65. In the report, MLV & Co noted, “Make no mistake about it, this is a valuation call. NYMT shares...

In a report published Thursday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $82.00 to $96.00. In the report, MLV & Co noted, “Yesterday, LGND reported a strong 4Q, beating recently raised guidance...

In a report published Wednesday, MLV & Co analyst Michael D. Peterson downgraded the rating on Royal Gold (NASDAQ: RGLD) from Buy to Hold, and removed the $65.00 price target. In the report, MLV & Co noted, “Year-to-date performance of Royal Gold has meaningfully outpaced that of gold, the...

In a report published Wednesday, MLV & Co analyst Ryan Meliker downgraded the rating on Apartment Investment and Management (NYSE: AIV) from Buy to Hold, but reiterated the $34.00 price target. In the report, MLV & Co noted, “We are downgrading AIV to HOLD on the view that the stock's...

In a report published Monday, MLV & Co analyst Ryan Meliker initiated coverage on RLJ Lodging Trust (NYSE: RLJ) with a Buy rating and $29.00 price target. In the report, MLV & Co noted, “We are initiating coverage of RLJ Lodging Trust with a BUY-rating and a $29 year-end price target. We...

In a report published Friday, MLV & Co analyst Ryan Meliker upgraded the rating on DiamondRock Hospitality Company (NYSE: DRH) from Hold to Buy, and raised the price target from $11.00 to $13.00. In the report, MLV & Co noted, “We are upgrading DRH to BUY driven by our view that the...

In a report published Tuesday, MLV & Co analyst Richard Eckert initiated coverage on ARMOUR Residential REIT (NYSE: ARR) with a Buy rating and $5.00 price target. In the report, MLV & Co noted, “We are initiating coverage of ARR with a Buy rating and $5 price target. Currently the stock is...

In a report published Tuesday, MLV & Co analyst Richard Eckert initiated coverage on Dynex Capital (NYSE: DX) with a Buy rating and $9.00 price target. In the report, MLV & Co noted, “We are initiating coverage of DX with a Buy rating and $9 price target. DX shares are now trading at...

In a report published Tuesday, MLV & Co analyst Richard Eckert initiated coverage on Hatteras Financial Corp. (NYSE: HTS) with a Buy rating and $21.00 price target. In the report, MLV & Co noted, “We are initiating coverage of HTS with a Buy rating and $21 price target. Currently trading...

MLV & Co downgraded Uroplasty (NASDAQ: UPI) from Buy to Hold and announced a $3.00 price target. MLV & Co noted, "Given our expectations for low growth over the next year and the recent approval of two competitive products for OAB from companies with much greater marketing prowess (and...

In a report published Wednesday, MLV & Co. reiterated its Buy rating on Royal Gold (NASDAQ: RGLD), and raised its price target from $82.00 to $92.00. MLV noted, “Amid rising macro economic concerns, contracting micro productivity, and favorable sub-sector capital in-flows, Royal Gold is well...

MLV & Co reiterates its Buy rating with a $4.50 price target on ImmunoCellular Therapeutics (NYSE: IMUC) as the company gets its listing on the NYSE starting next week. MLV & Co comments, "We view this move as an affirmation of the company's commitment to growing their pipeline, and...